Fusion Pharmaceuticals Inc. is a clinical-stage oncology company that develops radiopharmaceuticals as precision medicines to selectively deliver alpha particle payloads to tumors. Its lead product candidate, FPI-1434, is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company collaborates with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer while also progressing their earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers.